Goss GD, et al. - In this secondary analysis of the LUX-Lung 8 trial involving 245 clinically selected patients, researchers examined how ERBB family mutations are associated with outcomes of patients with lung squamous cell carcinoma who received treatment with afatinib dimaleate or erlotinib hydrochloride. They noted tumors with ≥ 1 ERBB mutation in 21.6% of patients. Afatinib treatment led to improved progression-free survival and overall survival vs erlotinib treatment among patients with ERBB wild-type tumors; however, more pronounced effects were evident among patients with tumors having at ≥ 1 ERBB family mutation, with the largest benefits observed among those with HER2 mutations. Hence, findings suggested the utility of ERBB mutations, particularly HER2 mutations, as a biomarker in identifying patients with lung squamous cell carcinoma who would derive additional benefit from afatinib.